Anti-PTPRJ (ab1) antibody produced in chicken

Protein-tyrosine phosphatase receptor type J (PTPRJ/CD148) is present predominatly in epithelial cells, various tumor cell lines and in lymphocytes. PTPRJ is commonly referred to as CD148 or DEP1.

Immunogen Sequence: GI # 18860900, sequence 206-292

Recombinant protein tyrosine phosphatase, receptor type, J

Protein-tyrosine phosphatase receptor type J (PTPRJ/CD148) is a protein tyrosine phosphatase. It is a negative regulator of T-cell receptor (TCR)-mediated activation of T cells. CD148 affects TCR signaling by interfering with the phosphorylation of phospholipase Cγ1 (PLCγ1) and LAT. CD148 dephosphorylates platelet-derived growth factor β-receptor, resulting in reduction in cell proliferation. CD148 also participates in functioning of cell-cell contacts and adherens junctions. It interacts with p120(ctn), a component of adherens junctions. CD148 associates with receptor tyrosine kinase RET and modulates the tumor phenotype associated with chimeric RET/papillary thyroid carcinoma oncogenes. It dephosphorylates p85 regulatory subunit of phosphoinositide 3-kinase (PI3K) and ERK1/2 (Extracellular signal-regulated kinases). It dephosphorylates and stabilizes epidermal growth factor receptor (EGFR). CD148 negatively regulates Fms-like tyrosine kinase-3 (FLT3) phosphorylation and signaling. It is up-regulated in humans suffering from rheumatoid arthritis and down-regulated in breast tumors. CD148 is a positive regulator of platelet activation and thrombosis.

Solution in phosphate buffered saline containing 0.02% sodium azide.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.